Outsourcing Outlook

More crucial biomanufacturing operations are expected to be outsourced.

CDMOs and CMOs face weak economic recovery, consolidation, and globalization.

Covance's deal with sanofi-aventis demonstrates the power of scale and scope.

Post recession and beyond, which contract service providers will still be standing?

Global pharmaceutical companies could have a problem getting rid of redundant facilities.

Changing demands in drug development lead to new service combinations and models.

Relationship management is a limiting factor to growth in biomanufacturing outsourcing.

Rising labor costs in China may result in increased competition for higher value services.

Eli Lilly faces up to the new realities of the bio/pharmaceutical industry through outsourcing.

Restructuring in the biopharmaceutical industry is renewing a focus on resource optimization.

CMOs' business model has all of the flaws of the captive model it is meant to replace.

Strategic rather than tactical considerations are driving biopharmaceutical outsourcing.

Contract organizations waiting for the pipeline to come roaring back are kidding themselves.

A new analysis highlights growth drivers and challenges for clinical supply-chain services.

Contract-service providers are expanding their offerings in this slow-growth environment.

In the current slow growth environment, service providers are looking to tactical expansions, as well as more ambitious strategic service expansions.

As the pharmaceutical industry looks to emerging markets, corruption becomes an important issue.

A joint biopharmaceutical manufacturing facility in India by Kenwell and Boehringer Ingelheim ushers in new era.

Pharma companies that sell redundant facilities could endanger their supply chains.

A major CRO ventures further into proprietary drug development.

Despite the market downturn, private equity investors are lining up for pharmaceutical services.

Despite the market downturn and financial meltdown, private equity investors are lining up for pharmaceutical services businesses.

When the business environment returns to "normal," our industry may appear quite different.

The financial crisis could lead to consolidation in the contract services industry.

Dire circumstances are driving major drug companies to seek out CRO partners. This article contains bonus online-exclusive material.

The European dose CMO sector appears to be very vibrant, probably more so than the market in the US.

The financial crisis could lead to consolidation in the contract services industry.

Despite challenges, contract manufacturers in Europe are enjoying considerable success.

Early development spending has decreased sharply as industry responds to the financial crisis.

As offshore savings decline, pharmaceutical companies still have a lot of work to do to reduce costs.